Уважаемые коллеги, доброго времени суток! Представляем вам испанское научное издание Pulmonology. Журнал имеет первый квартиль, издается в Elsevier Espana, его SJR за 2022 г. равен 1,641, импакт-фактор 9,216, печатный ISSN - 2531-0429, электронный - 2531-0437, предметная область Ингаляции и респираторная медицина. Вот так выглядит обложка:
Редактором является Николино Амброзино, контактные данные - nico.ambrosino@gmail.com, rppneu@elsevier.com.
Данный официальный журнал Португальского общества пульмонологии (Sociedade Portuguesa de Pneumologia/SPP) публикует 6 номеров в год, в основном о заболеваниях дыхательной системы у взрослых и клинических исследованиях. Работа может варьироваться от рецензируемых оригинальных статей до обзорных статей, редакционных статей и статей с общественным мнением. Журнал печатается на английском языке и находится в свободном доступе на его веб-странице, а также в Medline и других базах данных.
Адрес издания - https://www.sciencedirect.com/journal/pulmonology
Пример статьи, название - Stratifying risk outcomes among adult COVID-19 inpatients with high flow oxygen: The R4 score. Заголовок (Abstract)
Background
High flow oxygen therapy (HFO) is a widely used intervention for pulmonary complications. Amid the coronavirus infectious disease 2019 (COVID-19) pandemic, HFO became a popular alternative to conventional oxygen supplementation therapies. Risk stratification tools have been repurposed –and new ones developed– to estimate outcome risks among COVID-19 patients. This study aims to provide a simple risk stratification system to predict invasive mechanical ventilation (IMV) or death among COVID-19 inpatients on HFO.
Methods
Among 529 adult inpatients with COVID-19 pneumonia, we selected unadjusted clinical risk factors for developing the composite endpoint of IMV or death. The risk for the primary outcome by each category was estimated using a Cox proportional hazards model. Bootstrapping was used to validate the results.
Results
Age above 62, eGFR under 60 ml/min, room air SpO2 ≤89 % upon admission, history of hypertension, history of diabetes, and any comorbidity (cancer, cardiovascular disease, COPD/ asthma, hypothyroidism, or autoimmune disease) were considered for the score. Each of the six criteria scored 1 point. The score was further simplified into 4 categories: 1) 0 criteria, 2) 1 criterion, 3) 2-3 criteria, and 4) ≥4 criteria. Taking the first category as the reference, risk estimates for the primary endpoint were HR; 2.94 [1.67 – 5.26], 4.08 [2.63 – 7.05], and 6.63 [3.74 – 11.77], respectively. In ROC analysis, the AUC for the model was 0.72.
Conclusions
Our score uses simple criteria to estimate the risk for IMV or death among COVID-19 inpatients with HFO. Higher category reflects consistent increases in risk for the endpoint.
Keywords: Coronavirus; Risk; Respiratory distress syndrome; Oxygen inhalation therapy
Abbreviations
HFO; High flow oxygen therapy; COVID-19; Coronavirus infectious disease 2019; IMV; invasive mechanical ventilation; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; COT; conventional oxygen therapy; NIV; non-invasive ventilation; RT-PCR; reverse transcriptase polymerase chain reaction; IV; intravenous; IL-6; interleukin-6; SOFA; Sequential Organ Failure Assessment; PSI; Pneumonia Severity Index; NEWS 2; National Early Warning Score 2; FiO2; fraction of inspired oxygen; LDH; lactate dehydrogenase; CRP; C-reactive protein; BNP; brain natriuretic peptide; HS; highly sensitive; IQR; interquartile range; HR; hazard ratio; ROC; receiver operating characteristic; AUC; area under the curve; CVD; cardiovascular disease; COPD; chronic obstructive pulmonary disease